Local tirofiban infusion has been reported as a rescue strategy for intracranial atherosclerotic stenosis (ICAS)-related stroke. However, the long-term outcomes of local tirofiban infusion during endovascular reperfusion therapy (ERT) for ICAS-related stroke are still uncertain. This study aimed to investigate the long-term outcomes of local tirofiban infusion during ERT. We retrospectively analyzed acute patients with ICAS-related stroke who were treated with local tirofiban as a rescue strategy during ERT. The primary outcomes were ischemic stroke, transient ischemic stroke (TIA), and stroke-related death within 30 days. Secondary outcomes included ischemic stroke and TIA beyond 30 days and up to 2 years after ERT in the corresponding treated vessel, symptomatic brain hemorrhage, any stroke, and non-stroke-related death. During a median follow-up of 24.0 months, 12 patients developed an ischemic stroke and TIA (4 within 30 days and 8 afterward). The 1-year risk of stroke and TIA was 9.2% (95% confidence interval, 8.0–18.6%). This study demonstrates that 1-year outcomes of local tirofiban infusion were comparable to the results of intracranial stenting in patients with symptomatic ICAS. Local tirofiban infusion for ICAS-related stroke may be a feasible rescue strategy that can have a bridging role until the maximum effect of antiplatelet agents is achieved.
BACKGROUND: This study aimed to investigate whether net water uptake (NWU) is associated with 3-month catastrophic functional outcome (modified Rankin Scale score, 5–6) and to develop predictive models with preprocedural factors, including NWU, in patients with large infarcts who underwent endovascular thrombectomy. METHODS: This multicenter observational cohort study conducted in Korea included patients with anterior circulation stroke and an Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of ≤5 receiving endovascular thrombectomy between 2015 and 2023. NWU, a quantitative imaging biomarker reflecting the degree of hypoattenuation on noncontrast computed tomography, was measured across the entire ASPECTS region (ASPECTS10-NWU), and its association with catastrophic functional outcome was assessed using a mixed-effects logistic regression model, adjusting for age, sex, prestroke modified Rankin Scale score, baseline National Institutes of Health Stroke Scale score, baseline ASPECTS, onset-to-baseline noncontrast computed tomography time, and intravenous tissue-type plasminogen activator, with hospital included as a random effect. Moreover, a predictive model has been developed with preprocedural factors that were significant covariates from the mixed-effects logistic regression analysis. RESULTS: A total of 255 patients were included (mean age, 71.0±12.6 years; 54.9% male). The median ASPECTS10-NWU was 3.0% (interquartile range, 1.9%–4.1%). Higher ASPECTS10-NWU was independently associated with catastrophic functional outcome (adjusted odds ratio, 1.70 [95% CI, 1.33–2.17]; P <0.001). The model integrating ASPECTS10-NWU with preprocedural variables suggested predicted catastrophic functional outcome probabilities; as ASPECTS10-NWU and baseline National Institutes of Health Stroke Scale score increased, the marginal probability of catastrophic functional outcome increased in all age (<80 and ≥80 years) and prestroke modified Rankin Scale score (0–1 and 2–4) groups, with the patients aged ≥80 years and with prestroke modified Rankin Scale score of 2 to 4 having higher outcome probability. CONCLUSIONS: Elevated ASPECTS10-NWU is strongly associated with catastrophic functional outcome in patients with large infarcts treated with endovascular thrombectomy. Integrating the ASPECTS10-NWU with clinical variables may provide patient-specific prognostication that may assist clinicians in decision-making for endovascular thrombectomy in large infarcts.
Background: Regional eloquence of brainstem structures may contribute to neurological status in basilar artery occlusion (BAO) stroke. The corticospinal tract (CST) which is vulnerable to BAO is important for motor activity. This study investigated the impact of CST salvage on outcomes and its associated factors in patients with BAO treated with thrombectomy.Methods: We retrospectively investigated 88 patients with BAO admitted ≤24 h after onset and presented with motor deficits and who underwent thrombectomy. Patients with a pre-stroke modified Rankin Scale (mRS) score of 4–5 who did not undergo baseline brain computed tomography angiography were excluded. CST salvage was evaluated using follow-up imaging (magnetic resonance imaging [MRI] or computed tomography when MRI was not available) after thrombectomy. A good outcome was defined as a 3-month mRS score of ≤2 or 3 if a patient's pre-stroke mRS score was 3. The associations between CST salvage and outcomes and clinical parameters were analyzed using logistic regression analyses.Results: Thirty-nine (44.3%) patients had CST salvage and the same number of patients had good outcomes. CST salvage was independently associated with a good outcome [adjusted odds ratio (aOR): 18.52, 95% confidence interval (CI): 4.31–79.67, p < 0.001]. After adjusting for confounders, atrial fibrillation (aOR: 3.92, 95% CI: 1.18–13.00, p = 0.026), location of occlusion (mid-BAO; aOR: 0.21, 95% CI: 0.06–0.72, p = 0.013), length of occlusion (involved segment of BAO <2; aOR: 4.77, 95% CI: 1.30–17.59, p = 0.019), and onset-to-puncture-time ≤180 min (aOR: 4.84, 95% CI: 1.13–20.75, p = 0.034) were significantly associated with CST salvage.Conclusion: CST salvage was associated with good functional outcomes in patients with BAO treated with thrombectomy. The presence of atrial fibrillation, location and length of BAO may predict CST salvage after thrombectomy, and rapid treatment with thrombectomy may protect this eloquent tract in these patients.
Background and Clinical Significance: Anticoagulation timing after atrial fibrillation (AF)-related ischemic stroke is uncertain when hemorrhagic transformation (HT) is progressive. Although early direct oral anticoagulant (DOAC) initiation is supported in selected patients, evidence is limited for parenchymal hemorrhage or progressive HT. Case Presentation: A 72-year-old man receiving aspirin therapy, in whom AF was newly diagnosed on admission, presented with multi-territorial ischemic stroke and HT. He was febrile, with a C-reactive protein level of 15.54 mg/dL, and underwent serial abdominal computed tomography (CT) to investigate the source of fever. Given concern regarding intracranial bleeding associated with HT, apixaban 2.5 mg twice daily was initiated on day 4 but discontinued on day 6 because of progressive HT. No antithrombotic therapy was subsequently administered. CT on day 2 showed no left atrial appendage (LAA) filling defect. On day 10, after reduction in inflammatory activity, repeat CT demonstrated a new 15-mm LAA filling defect radiologically suggestive of thrombus. The defect was no longer visible on day 16. Transesophageal echocardiography on day 19 showed no intracardiac thrombus. Apixaban was resumed on day 35 after radiographic HT resolution. He received antithrombotic therapy for only 2 of the first 35 days after stroke onset. Conclusions: A transient LAA filling defect was observed during a prolonged antithrombotic-free interval and was not visualized on follow-up CT. Although contemporaneous dedicated cardiac imaging was unavailable and slow flow or contrast-mixing artifact could not be excluded, this serial observation raises the possibility of a transient thrombotic phenomenon during anticoagulation interruption.
Background/Objectives: Blood-based biomarkers may help prioritize patients for confirmatory amyloid testing. We compared amyloid positron emission tomography (PET) utilization and diagnostic yield between memory-clinic periods before and after plasma oligomerized amyloid-β (oAβ) testing became routinely available. Methods: This retrospective, single-center, before-and-after cohort study included 1125 index evaluations for cognitive complaints (660 pre-oAβ; 465 post-oAβ). The primary outcome was PET diagnostic yield, defined as the proportion of amyloid-positive scans among patients undergoing 18F-florapronol PET. Secondary analyses assessed PET utilization, PET examinations per amyloid-positive case, and, within the post-oAβ period, the association between oAβ ≥ 0.78 ng/mL and subsequent PET use. Results: PET utilization did not differ significantly between the post- and pre-oAβ periods (10.1% vs. 7.7%; odds ratio [OR], 1.34; 95% confidence interval [CI], 0.89–2.03; p = 0.165). PET diagnostic yield was higher in the post-oAβ period (78.7% vs. 33.3%; OR, 7.40; 95% CI, 2.98–18.37; p < 0.001), including after adjustment for age and sex (adjusted OR [aOR], 6.89; 95% CI, 2.74–17.29). PET examinations per amyloid-positive case were 1.27 and 3.00, respectively. Within the post-oAβ period, oAβ ≥ 0.78 ng/mL was associated with subsequent PET use (aOR, 2.78; 95% CI, 1.49–5.18), with similar estimates after multiple imputation of missing covariates. Conclusions: Amyloid PET yield was higher after routine oAβ testing was introduced than before, without a significant increase in PET use. Because anti-amyloid treatment awareness and referral practices also changed over time, this difference cannot be attributed to oAβ testing itself, and the higher yield does not indicate improved assay accuracy. These findings support prospective evaluation of blood-biomarker-guided triage.
1 May 2024 in Journal of the Korean Neurological Association